Atea Pharmaceuticals is set to initiate a Phase 3 study for its hepatitis C treatment after a successful Phase 2 trial, where 98% of patients achieved a sustained virologic response. The regimen, combining bemnifosbuvir and ruzasvir, demonstrated strong efficacy with a reduced pill count and no serious side effects. Atea aims to address the evolving patient demographic and improve adherence among high-risk groups, as it seeks to regain momentum following previous setbacks.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.